Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.

Biotech Giants: Who Manages SG&A Costs Better?

__timestampMorphoSys AGWave Life Sciences Ltd.
Wednesday, January 1, 201496890002999000
Thursday, January 1, 20151043100010393000
Friday, January 1, 2016961800015994000
Sunday, January 1, 20171234800026975000
Monday, January 1, 20182831024139509000
Tuesday, January 1, 20195933614748869000
Wednesday, January 1, 202015914594142510000
Friday, January 1, 202119980000046105000
Saturday, January 1, 20229022500050513000
Sunday, January 1, 20239253800051292000
Loading chart...

Infusing magic into the data realm

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. MorphoSys AG and Wave Life Sciences Ltd. have been navigating this challenge since 2014. Over the past decade, MorphoSys AG has seen a significant increase in SG&A expenses, peaking in 2021 with a 1,900% rise from 2014. In contrast, Wave Life Sciences Ltd. has maintained a more stable trajectory, with a 1,600% increase over the same period.

While MorphoSys AG's expenses surged dramatically in 2020, Wave Life Sciences Ltd. managed a steadier climb, suggesting a more controlled approach to cost management. This comparison highlights the diverse strategies employed by biotech firms in optimizing operational costs, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025